Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Xenon Pharmaceuticals Inc. (XENE)

Xenon Q2 net loss widens to $110.7 million; azetukalner NDA still on track for Q3 2026

Negative Impact 3 of 5 earnings Written later

Xenon Pharmaceuticals reported a second-quarter 2026 net loss of $110.7 million, or $1.11 per share, up from $84.7 million, or $1.07 per share, a year earlier, as research and development spending rose to $99.2 million. The company had no revenue in the quarter, and it said it remains on track to submit an NDA for azetukalner in the third quarter of 2026, with cash of $1.2 billion and runway into 2029.

Key points

  • Q2 2026 net loss was $110.7 million ($1.11 per share), compared with $84.7 million ($1.07 per share) in Q2 2025.
  • Research and development expenses were $99.2 million, up from $75.0 million, driven by azetukalner Phase 3 studies and NDA manufacturing activities.
  • Cash, cash equivalents and marketable securities were $1,245.1 million as of June 30, 2026, versus $586.0 million at December 31, 2025, with runway into 2029.
  • The company said lower revenue from its Neurocrine Biosciences collaboration contributed to the larger loss.

The filing

CompanyXenon Pharmaceuticals Inc. (XENE)
Form8-K, current report
Filed with the SECAug 6, 2026, 4:11 PM ET
Accession number0001193125-26-338019

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.